|
Pharsight Monthly Summary
|
JUNE, 2024
|
Recent happenings in
patent protected
drugs.
|
|
|
Pharsight Monthly Summary
|
JUNE, 2024
|
Recent happenings in
patent protected
drugs.
|
|
|
|
| |
At a Glance
| |
60
|
new drug
patents
introduced
|
| |
|
|
|
| |
Companies who recently
launched drugs
| |
|
|
| |
Drugs not protected by their main patents
| |
|
|
| |
Drug patents lapsed
|
Drug
|
Patent
|
Patent expiry
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABILIFY MYCITE KIT
|
8017615
|
Jun, 2024
|
ABRAXANE
|
7923536*PED
|
Jun, 2024
|
ABRAXANE
|
8138229*PED
|
Jun, 2024
|
ABRAXANE
|
8314156*PED
|
Jun, 2024
|
ADMELOG SOLOSTAR
|
8992486
|
Jun, 2024
|
APIDRA SOLOSTAR
|
8992486
|
Jun, 2024
|
BELVIQ
|
8946207
|
Jun, 2024
|
BELVIQ XR
|
8946207
|
Jun, 2024
|
ILEVRO
|
7947295
|
Jun, 2024
|
LANTUS SOLOSTAR
|
8992486
|
Jun, 2024
|
MOVANTIK
|
7056500
|
Jun, 2024
|
MOVANTIK
|
7056500
|
Jun, 2024
|
NUVIGIL
|
7132570*PED
|
Jun, 2024
|
NUVIGIL
|
7132570*PED
|
Jun, 2024
|
NUVIGIL
|
7132570*PED
|
Jun, 2024
|
NUVIGIL
|
7132570*PED
|
Jun, 2024
|
NUVIGIL
|
7132570*PED
|
Jun, 2024
|
PEPAXTO
|
6992207
|
Jun, 2024
|
SOLIQUA 100/33
|
8992486
|
Jun, 2024
|
TOUJEO MAX SOLOSTAR
|
8992486
|
Jun, 2024
|
TOUJEO SOLOSTAR
|
8992486
|
Jun, 2024
|
TPOXX
|
8124643
|
Jun, 2024
|
TPOXX
|
8530509
|
Jun, 2024
|
TPOXX
|
8802714
|
Jun, 2024
|
TPOXX
|
8124643
|
Jun, 2024
|
TPOXX
|
8530509
|
Jun, 2024
|
TPOXX
|
8802714
|
Jun, 2024
|
XIFAXAN
|
7045620
|
Jun, 2024
|
XIFAXAN
|
7612199
|
Jun, 2024
|
XIFAXAN
|
7902206
|
Jun, 2024
|
XIFAXAN
|
8158644
|
Jun, 2024
|
XIFAXAN
|
8158781
|
Jun, 2024
|
XIFAXAN
|
8835452
|
Jun, 2024
|
XIFAXAN
|
8853231
|
Jun, 2024
|
XIFAXAN
|
7045620
|
Jun, 2024
|
XIFAXAN
|
7612199
|
Jun, 2024
|
XIFAXAN
|
7902206
|
Jun, 2024
|
XIFAXAN
|
8158644
|
Jun, 2024
|
XIFAXAN
|
8158781
|
Jun, 2024
|
XIFAXAN
|
8835452
|
Jun, 2024
|
XIFAXAN
|
8853231
|
Jun, 2024
|
XIFAXAN
|
7045620
|
Jun, 2024
|
XIFAXAN
|
7612199
|
Jun, 2024
|
XIFAXAN
|
7902206
|
Jun, 2024
|
XIFAXAN
|
8158644
|
Jun, 2024
|
XIFAXAN
|
8158781
|
Jun, 2024
|
XIFAXAN
|
8835452
|
Jun, 2024
|
XIFAXAN
|
8853231
|
Jun, 2024
|
XYREM
|
7668730
|
Jun, 2024
|
XYREM
|
7765106
|
Jun, 2024
|
XYREM
|
7765107
|
Jun, 2024
|
|
|
|
| |
Newly introduced Drug
Patents
|
Drug
|
Patent
|
Patent expiry
|
AKEEGA
|
11986468
|
Jul, 2037
|
AKEEGA
|
11986469
|
Jul, 2037
|
AKEEGA
|
11992486
|
Jul, 2037
|
AUGTYRO
|
10294242
|
Jul, 2036
|
AUGTYRO
|
11452725
|
Jul, 2036
|
AUGTYRO
|
9714258
|
Jan, 2035
|
BORTEZOMIB
|
12005069
|
Sep, 2042
|
CONTRAVE
|
11998542
|
Jul, 2034
|
DUOBRII
|
11986527
|
Nov, 2031
|
EPSOLAY
|
11986456
|
Feb, 2040
|
IGALMI
|
11998528
|
Jan, 2043
|
IQIRVO
|
11185519
|
Mar, 2037
|
IQIRVO
|
11331292
|
Mar, 2037
|
IQIRVO
|
11850223
|
Mar, 2037
|
IQIRVO
|
11857523
|
Mar, 2037
|
IQIRVO
|
7632870
|
Sep, 2024
|
IQIRVO
|
7943661
|
Sep, 2024
|
JULUCA
|
12011506
|
Sep, 2038
|
LILETTA
|
12004992
|
Oct, 2033
|
LIQREV
|
12005062
|
Dec, 2038
|
MYCAPSSA
|
11986529
|
Sep, 2029
|
NORLIQVA
|
12005141
|
Feb, 2041
|
OGSIVEO
|
12011434
|
May, 2043
|
OGSIVEO
|
12011435
|
May, 2043
|
PEDMARK
|
11992530
|
Jul, 2039
|
PEDMARK
|
11998604
|
Jul, 2039
|
PHEXXI
|
11992472
|
Mar, 2033
|
QINLOCK
|
12023325
|
Aug, 2040
|
QINLOCK
|
12023326
|
Aug, 2040
|
QINLOCK
|
12023327
|
Aug, 2040
|
QINLOCK
|
12023328
|
Dec, 2040
|
RINVOQ
|
11976077
|
Oct, 2036
|
RINVOQ
|
11993605
|
Oct, 2036
|
RINVOQ
|
11993606
|
Oct, 2036
|
RINVOQ LQ
|
10981923
|
Oct, 2036
|
RINVOQ LQ
|
11186584
|
Oct, 2036
|
RINVOQ LQ
|
11661425
|
Oct, 2036
|
RINVOQ LQ
|
11680069
|
Oct, 2036
|
RINVOQ LQ
|
11718627
|
Oct, 2036
|
RINVOQ LQ
|
11773105
|
Oct, 2036
|
RINVOQ LQ
|
8962629
|
Jan, 2031
|
RINVOQ LQ
|
9951080
|
Oct, 2036
|
RISVAN
|
11752094
|
May, 2031
|
RYTELO
|
7494982
|
Dec, 2025
|
RYTELO
|
9375485
|
Mar, 2033
|
RYTELO
|
9388415
|
Sep, 2024
|
RYTELO
|
9388416
|
Sep, 2024
|
SPINRAZA
|
12013403
|
Mar, 2036
|
SUNOSI
|
12005036
|
Dec, 2042
|
VEKLURY
|
11975012*PED
|
Nov, 2041
|
VEKLURY
|
11975017*PED
|
Jan, 2039
|
VIGAFYDE
|
12016857
|
Aug, 2039
|
WEGOVY
|
12029779
|
Oct, 2038
|
XYREM
|
11986446
|
Mar, 2033
|
XYWAV
|
11986446
|
Mar, 2033
|
ZORYVE
|
11992480
|
Jun, 2037
|
ZORYVE
|
12005051
|
Jun, 2037
|
ZORYVE
|
12005052
|
Jun, 2037
|
ZORYVE
|
12011437
|
Jun, 2037
|
ZORYVE
|
12016848
|
Jun, 2037
|
|
|
|
| | What's new on Pharsight! | Find the answers you need on Drugs. Are you looking for accurate and reliable information on drugs and generics? Look no further! Our FAQ page is packed with answers to some of the most commonly asked questions about drugs. Visit and bookmark our FAQ page today! Bonus - Don't see your question answered there? Contact us, and we'll be happy to help! Check out FAQ page Shoot first, and win big! Figure out the drugs that are about to enter the NCE-1 period to stay ahead of your generic launch strategy! Want to be first-to-market with your generic drugs? Stay ahead of the game with our exclusive list of drugs facing patent challenges updated every month. Check out NCE-1 period list |
|
|
|
| | Our insights are consumed by 1000+ leading pharma
companies |
|
| |
|
|
© 2024 GreyB Research |
|
|